Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
8 Jul 22
NT 10-Q
Notice of late quarterly filing
17 May 22
Current reports
8-K
Results of Operations and Financial Condition
25 Mar 24
8-K
Regulation FD Disclosure
12 Feb 24
8-K
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
1 Feb 24
8-K
Entry into a Material Definitive Agreement
31 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jan 24
8-K
Regulation FD Disclosure
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
27 Sep 23
8-K
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
21 Sep 23
Registration and prospectus
424B3
Prospectus supplement
28 Mar 24
S-3
Shelf registration
28 Feb 24
D
$15.00 mm in equity / options / securities to be acquired, sold $15.00 mm, 13 investors
14 Feb 24
S-8
Registration of securities for employees
13 Oct 23
424B1
Prospectus with pricing info
2 Jun 23
S-1/A
IPO registration (amended)
31 May 23
FWP
Free writing prospectus
15 May 23
S-1/A
IPO registration (amended)
12 May 23
S-1
IPO registration
5 May 23
D
$200.00 k in equity / options / securities to be acquired, sold $200.00 k, 1 investor
17 Feb 23
Proxies
DEF 14A
Definitive proxy
25 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
DEFA14A
Additional proxy soliciting materials
1 Sep 23
DEF 14A
Definitive proxy
21 Jul 23
PRE 14A
Preliminary proxy
11 Jul 23
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
15 Aug 22
DEF 14A
Definitive proxy
8 Aug 22
PRE 14A
Preliminary proxy
5 Aug 22
PRE 14A
Preliminary proxy
27 Jul 22
Other
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
2 Jun 23
CORRESP
Correspondence with SEC
31 May 23
CORRESP
Correspondence with SEC
31 May 23
CORRESP
Correspondence with SEC
24 May 23
CORRESP
Correspondence with SEC
24 May 23
CORRESP
Correspondence with SEC
23 May 23
UPLOAD
Letter from SEC
9 May 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
Ownership
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Stonepine Capital Management, LLC
9 Feb 24
SC 13G
HIRSCHMAN ORIN
7 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Melissa Tosca
3 Oct 23
4
Eric Joseph Daniels
3 Oct 23
4
Brian M. Strem
3 Oct 23
4
PRAVEEN TYLE
3 Oct 23
4
Aron Shapiro
3 Oct 23